Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hull

Showing results (621-630 of 699) with videos related to

Pageof 70
Sort By:
Annals of Internal Medicine|July 13, 2010
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trialRussell D Hull, Sebastian M Schellong, Victor F Tapson, et al.
Nano Letters|February 28, 2017
Unbalanced Hole and Electron Diffusion in Lead Bromide PerovskitesGiselle A Elbaz, Daniel B Straus, Octavi E Semonin, et al.
Annals of Internal Medicine|April 21, 2004
D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic reviewPaul D Stein, Russell D Hull, Kalpesh C Patel, et al.
JAMA|May 2, 1990
Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacementR D Hull, G E Raskob, M Gent, et al.
The Journal of Invasive Cardiology|May 5, 2010
Outcomes with retrievable inferior vena cava filtersMuhammad Janjua, Fahad Younas, Irfan Moinuddin, et al.
Archives of Internal Medicine|July 25, 2000
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial InvestigatorsR D Hull, G F Pineo, C Francis, et al.
Archives of Internal Medicine|August 1, 1992
Optimal therapeutic level of heparin therapy in patients with venous thrombosisR D Hull, G E Raskob, D Rosenbloom, et al.
Human Molecular Genetics|May 1, 2015
The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteinsMark S Moehle, João Paulo Lima Daher, Travis D Hull, et al.
Archives of Internal Medicine|July 25, 2000
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial InvestigatorsR D Hull, G F Pineo, C Francis, et al.
Archives of Internal Medicine|February 10, 1997
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspectiveR D Hull, G E Raskob, D Rosenbloom, et al.
Pageof 70

Showing results (621-630 of 699) with videos related to

Sort By:
Pageof 70
Annals of Internal Medicine|July 13, 2010
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trialRussell D Hull, Sebastian M Schellong, Victor F Tapson, et al.
Nano Letters|February 28, 2017
Unbalanced Hole and Electron Diffusion in Lead Bromide PerovskitesGiselle A Elbaz, Daniel B Straus, Octavi E Semonin, et al.
Annals of Internal Medicine|April 21, 2004
D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic reviewPaul D Stein, Russell D Hull, Kalpesh C Patel, et al.
JAMA|May 2, 1990
Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacementR D Hull, G E Raskob, M Gent, et al.
The Journal of Invasive Cardiology|May 5, 2010
Outcomes with retrievable inferior vena cava filtersMuhammad Janjua, Fahad Younas, Irfan Moinuddin, et al.
Archives of Internal Medicine|July 25, 2000
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial InvestigatorsR D Hull, G F Pineo, C Francis, et al.
Archives of Internal Medicine|August 1, 1992
Optimal therapeutic level of heparin therapy in patients with venous thrombosisR D Hull, G E Raskob, D Rosenbloom, et al.
Human Molecular Genetics|May 1, 2015
The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteinsMark S Moehle, João Paulo Lima Daher, Travis D Hull, et al.
Archives of Internal Medicine|July 25, 2000
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial InvestigatorsR D Hull, G F Pineo, C Francis, et al.
Archives of Internal Medicine|February 10, 1997
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspectiveR D Hull, G E Raskob, D Rosenbloom, et al.
Pageof 70